Works by Jurczak, W.

Results: 62
    1
    2
    3
    4

    P1161: ASPEN: LONG‐TERM FOLLOW‐UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

    Published in:
    HemaSphere, 2022, v. 6, p. 1048, doi. 10.1097/01.HS9.0000847512.47964.b7
    By:
    • Dimopoulos, M.;
    • Opat, S.;
    • D'Sa, S.;
    • Jurczak, W.;
    • Lee, H.‐P.;
    • Cull, G.;
    • Owen, R. G.;
    • Marlton, P.;
    • Wahlin, B. E.;
    • Garcia‐Sanz, R.;
    • McCarthy, H.;
    • Mulligan, S.;
    • Tedeschi, A.;
    • Castillo, J. J.;
    • Czyz, J.;
    • Fernandez De Larrea Rodriguez, C.;
    • Belada, D.;
    • Libby, E.;
    • Matous, J.;
    • Motta, M.
    Publication type:
    Article
    5

    P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS‐3 TRIAL.

    Published in:
    HemaSphere, 2022, v. 6, p. 1028, doi. 10.1097/01.HS9.0000847420.24995.43
    By:
    • Zinzani, P. L.;
    • Özcan, M.;
    • Sapunarova, K.;
    • Jurczak, W.;
    • Hamed, A.;
    • Bouabdallah, K.;
    • Saydam, G.;
    • Geissler, K.;
    • Szomor, Á.;
    • Lazaroiu, M.;
    • Salar, A.;
    • Tempescul, A.;
    • Nalcaci, M.;
    • Gercheva, L.;
    • Egyed, M.;
    • Panayiotidis, P.;
    • Mongay Soler, L.;
    • Cao, A.;
    • Phelps, C.;
    • H Childs, B.
    Publication type:
    Article
    6

    P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 991, doi. 10.1097/01.HS9.0000847272.47630.ff
    By:
    • Eyre, T. A.;
    • Wang, M. L.;
    • Shah, N. N.;
    • Alencar, A. J.;
    • Gerson, J. N.;
    • Patel, M. R.;
    • Fakhri, B.;
    • Vandenberghe, E.;
    • Jurczak, W.;
    • Tan, X. N.;
    • Lewis, K. L.;
    • Fenske, T.;
    • Wang, Y.;
    • Coombs, C. C.;
    • Flinn, I.;
    • Lewis, D.;
    • Le Gouill, S.;
    • Gandhi, M.;
    • Chay, C.;
    • Palomba, M. L.
    Publication type:
    Article
    7

    P1100: BRUIN MCL‐321: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

    Published in:
    HemaSphere, 2022, v. 6, p. 990, doi. 10.1097/01.HS9.0000847268.67095.fc
    By:
    • Eyre, T. A.;
    • Shah, N. N.;
    • Le Gouill, S.;
    • Dreyling, M.;
    • Vandenberghe, E.;
    • Jurczak, W.;
    • Wang, Y.;
    • Cheah, C. Y.;
    • Gandhi, M.;
    • Chay, C.;
    • Sharman, J. P.;
    • Andorsky, D. J.;
    • Yin, M.;
    • Balbas, M.;
    • Kherani, J.;
    • Wang, M. L.
    Publication type:
    Article
    8
    9
    10

    P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR FOLLOW‐UP OF ELEVATE‐TN.

    Published in:
    HemaSphere, 2022, v. 6, p. 564, doi. 10.1097/01.HS9.0000845548.49291.01
    By:
    • Sharman, J. P.;
    • Egyed, M.;
    • Jurczak, W.;
    • Skarbnik, A.;
    • Patel, K.;
    • Flinn, I. W.;
    • Kamdar, M.;
    • Munir, T.;
    • Walewska, R.;
    • Fogliatto, L. M.;
    • Herishanu, Y.;
    • Banerji, V.;
    • Follows, G.;
    • Walker, P.;
    • Karlsson, K.;
    • Ghia, P.;
    • Janssens, A.;
    • Cymbalista, F.;
    • Ferrant, E.;
    • Wierda, W. G.
    Publication type:
    Article
    11
    12

    S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE‐RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST‐LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE‐CELL LYMPHOMA.

    Published in:
    HemaSphere, 2022, v. 6, p. 110, doi. 10.1097/01.HS9.0000843728.37710.5f
    By:
    • Wang, M. L.;
    • Jurczak, W.;
    • Jerkeman, M.;
    • Trotman, J.;
    • Zinani, P. L.;
    • Belada, D.;
    • Boccomini, C.;
    • Flinn, I. W.;
    • Giri, P.;
    • Goy, A.;
    • Hamlin, P. A.;
    • Hermine, O.;
    • Hernández‐Rivas, J.‐Á.;
    • Hong, X.;
    • Kim, S. J.;
    • Lewis, D.;
    • Mishima, Y.;
    • Özcan, M.;
    • Perini, G. F.;
    • Pocock, C.
    Publication type:
    Article
    13

    S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL.

    Published in:
    HemaSphere, 2022, v. 6, p. 109, doi. 10.1097/01.HS9.0000843724.38671.cf
    By:
    • Zelenetz, A.;
    • Jurczak, W.;
    • Ribrag, V.;
    • Linton, K.;
    • Collins, G.;
    • Lopéz‐Jiménez, J.;
    • Reddy, N.;
    • Mengarelli, A.;
    • Phillips, T.;
    • Musuraca, G.;
    • Sheehy, O.;
    • Li, J.;
    • Xu, W.;
    • Azoulay, M.;
    • Ghalie, R.;
    • Zinzani, P. L.
    Publication type:
    Article
    14
    15

    SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 142, doi. 10.1002/hon.3163_94
    By:
    • Thieblemont, C.;
    • Karimi, Y.;
    • Jurczak, W.;
    • Cheah, C. Y.;
    • Clausen, M. R.;
    • Cunningham, D.;
    • Do, Y. R.;
    • Lewis, D. J.;
    • Gasiorowski, R.;
    • Kim, T. M.;
    • van der Poel, M.;
    • Poon, M. L.;
    • Feldman, T.;
    • Linton, K. M.;
    • Sureda, A.;
    • Hutchings, M.;
    • Cottereau, A.;
    • Al Tabaa, Y.;
    • Stirner, M. Cota;
    • Liu, Y.
    Publication type:
    Article
    16
    17
    18
    19
    20

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
    By:
    • McDonald, A.;
    • Verburgh, E.;
    • Gotti, M.;
    • Pinto, A.;
    • Zaucha, J.;
    • Ivanov, V.;
    • Melnichenko, V.;
    • Mocikova, H.;
    • Ozcan, M.;
    • Patti, C.;
    • Farias, J.;
    • Goncalves, I.;
    • Kuchkova, O.;
    • Mayer, J.;
    • Saydam, G.;
    • Tomassetti, S.;
    • Pathiraja, K.;
    • Ryland, K.;
    • Chakraborty, S.;
    • Jurczak, W.
    Publication type:
    Article
    21

    A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 564, doi. 10.1002/hon.3164_422
    By:
    • Zinzani, P. L.;
    • Mayer, J.;
    • Benjamini, O.;
    • Berkovits, A.;
    • Glimelius, I.;
    • Stevens, D.;
    • Chaudhry, A.;
    • Demir, A. M.;
    • Sanz, R. G.;
    • Kim, W. S.;
    • Li, F.;
    • Halka, J.;
    • Marin‐Niebla, A.;
    • Ozcan, M.;
    • Paszkiewicz‐Kozik, E.;
    • Santoro, A.;
    • Ren, Y.;
    • Ogbu, U.;
    • Marinello, P.;
    • Jurczak, W.
    Publication type:
    Article
    22
    23
    24
    25
    26

    Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 353, doi. 10.1002/hon.3164_254
    By:
    • Abramson, J. S.;
    • Straus, D.;
    • Bartlett, N.;
    • Burke, J. M.;
    • Lynch, R. C.;
    • Domingo‐Domenech, E.;
    • Hess, B.;
    • Schuster, S.;
    • Linhares, Y.;
    • Ramchandren, R.;
    • Gandhi, M.;
    • Mowat, R.;
    • Shah, H.;
    • Jurczak, W.;
    • Re, A.;
    • Hahn, U.;
    • Prince, H. M.;
    • Ho, L.;
    • Guo, W.;
    • Jain, S.
    Publication type:
    Article
    27
    28

    GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 185, doi. 10.1002/hon.3163_116
    By:
    • Patel, K.;
    • Brown, J. R.;
    • Desikan, S. P.;
    • Nguyen, B.;
    • Won, H.;
    • Tantawy, S. I.;
    • McNeely, S. C.;
    • Marella, N.;
    • Ebata, K.;
    • Woyach, J. A.;
    • Tam, C. S.;
    • Eyre, T. A.;
    • Cheah, C. Y.;
    • Shah, N. N.;
    • Ghia, P.;
    • Jurczak, W.;
    • Balbas, M.;
    • Nair, B.;
    • Abada, P.;
    • Wang, C.
    Publication type:
    Article
    29

    PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 153, doi. 10.1002/hon.3163_102
    By:
    • Cheah, C. Y.;
    • Shah, N. N.;
    • Jurczak, W.;
    • Zinzani, P. Luigi;
    • Eyre, T. A.;
    • Ujjani, C. S.;
    • Izutsu, K.;
    • Ma, S.;
    • Flinn, I.;
    • Alencar, A. J.;
    • Lewis, D.;
    • Patel, K.;
    • Maddocks, K.;
    • Wang, Y.;
    • Munir, T.;
    • Zelenetz, A. D.;
    • Balbas, M.;
    • Tsai, D. E.;
    • Wang, C.;
    • Wang, M. L.
    Publication type:
    Article
    30
    31
    32
    33

    CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.21_2880
    By:
    • Batlevi, C. L.;
    • Salles, G.;
    • Tilly, H.;
    • Chaidos, A.;
    • McKay, P.;
    • Phillips, T.;
    • Assouline, S.;
    • Campbell, P.;
    • Ribrag, V.;
    • Damaj, G. Laurent;
    • Dickinson, M.;
    • Jurczak, W.;
    • Kaźmierczak, M.;
    • Opat, S.;
    • Radford, J. R.;
    • Schmitt, A.;
    • Rajarethinam, A.;
    • Shang, G.;
    • Morschhauser, F.
    Publication type:
    Article
    34
    35
    36

    SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.156_2880
    By:
    • Levy, M. Y.;
    • Grudeva‐Popova, Z.;
    • Trneny, M.;
    • Jurczak, W.;
    • Pylypenko, H.;
    • Jagadeesh, D.;
    • Andre, M.;
    • Nasta, S.;
    • Rechavi‐Robinson, D.;
    • Toffanin, S.;
    • Micallef, S.;
    • Attinger, A.;
    • Rouits, E.;
    • Dymkowska, M.;
    • Nauwelaerts, H.;
    • Woei‐A‐Jin, F. J. S. H.
    Publication type:
    Article
    37
    38
    39
    40

    ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
    By:
    • Vitolo, U.;
    • Witzig, T.E.;
    • Gascoyne, R.D.;
    • Scott, D.W.;
    • Zhang, Q.;
    • Jurczak, W.;
    • Özcan, M.;
    • Hong, X.;
    • Zhu, J.;
    • Jin, J.;
    • Belada, D.;
    • Bergua, J.M.;
    • Piazza, F.;
    • Mócikova, H.;
    • Molinari, A.L.;
    • Yoon, D.H.;
    • Cavallo, F.;
    • Tani, M.;
    • Izutsu, K.;
    • Kato, K.
    Publication type:
    Article
    41
    42

    A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
    By:
    • Zelenetz, A.;
    • Zinzani, P.;
    • Buske, C.;
    • Ribrag, V.;
    • Cunningham, D.;
    • Jurczak, W.;
    • Abrisqueta, P.;
    • Agajanian, R.;
    • Chaudhry, A.;
    • Kayyal, T.;
    • Wood, J.;
    • Llorin‐Sangalang, J.;
    • Brown, J.
    Publication type:
    Article
    43
    44

    UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 182, doi. 10.1002/hon.139_2629
    By:
    • Zinzani, P.;
    • Samaniego, F.;
    • Jurczak, W.;
    • Lech‐Maranda, E.;
    • Ghosh, N.;
    • Anz, B.;
    • Patten, P.;
    • Reeves, J.;
    • Leslie, L.A.;
    • Smolewski, P.;
    • Chavez, J.C.;
    • Scarfo, L.;
    • Derenzini, E.;
    • Burke, J.M.;
    • Sharman, J.;
    • Kolibaba, K.;
    • O'Connor, O.A.;
    • Cheah, C.Y.;
    • Miskin, H.P.;
    • Sportelli, P.
    Publication type:
    Article
    45
    46
    47
    48

    ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
    By:
    • Vitolo, U.;
    • Witzig, T.E.;
    • Gascoyne, R.D.;
    • Scott, D.W.;
    • Zhang, Q.;
    • Jurczak, W.;
    • Özcan, M.;
    • Hong, X.;
    • Zhu, J.;
    • Jin, J.;
    • Belada, D.;
    • Bergua, J.M.;
    • Piazza, F.;
    • Mócikova, H.;
    • Molinari, A.L.;
    • Yoon, D.H.;
    • Cavallo, F.;
    • Tani, M.;
    • Izutsu, K.;
    • Kato, K.
    Publication type:
    Article
    49
    50

    A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
    By:
    • Zelenetz, A.;
    • Zinzani, P.;
    • Buske, C.;
    • Ribrag, V.;
    • Cunningham, D.;
    • Jurczak, W.;
    • Abrisqueta, P.;
    • Agajanian, R.;
    • Chaudhry, A.;
    • Kayyal, T.;
    • Wood, J.;
    • Llorin‐Sangalang, J.;
    • Brown, J.
    Publication type:
    Article